Exhibit 10.20
***Text omitted and filed separately
Confidential Treatment Requested
Under 17 C.F.R.§§ 200.80
(b) (4)
And 240.24b-2
AMENDMENT NO. 2 TO SEMI-EXCLUSIVE BNP
DIAGNOSTIC LICENSE AGREEMENT
THIS AMENDMENT NO. 2 TO
SEMI-EXCLUSIVE BNP DIAGNOSTIC LICENSE AGREEMENT (this
“Amendment”), dated as of August 30, 2002 (the
“Amendment Date”), is entered into between BIOSITE
INCORPORATED, a Delaware corporation (“Biosite”),
having a place of business located at 11030 Roselle Street,
Suite D, San Diego, California 92121, and SCIOS INC., a
Delaware corporation (“Scios”), having a place of
business at 2450 Bay Shore Parkway, Mountain View, California
94043.
W I T N E S S E T H:
WHEREAS, the parties entered into a
Semi-Exclusive BNP Diagnostic License effective as of
December 30, 1996 (as amended, the
“Agreement”).
WHEREAS, the parties desire to amend
the Agreement in certain respects as set forth below, in order to
clarify the parties mutual understanding regarding the calculation
of milestones and royalties payable to Scios under the
Agreement.
NOW, THEREFORE, in consideration of
the foregoing premises and the mutual covenants set forth below,
the parties amend the Agreement and agree as follows:
1.
Amendments
.
1.1
Section 3.2 of the Agreement is
amended to add the following sentence at the end
thereof:
The parties acknowledge and agree
that the payments des
